{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03190278",
            "orgStudyIdInfo": {
                "id": "UCART123_01"
            },
            "organization": {
                "fullName": "Cellectis S.A.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
            "officialTitle": "Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
            "acronym": "AMELI-01",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-evaluating-safety-and-efficacy-of-in-patients-with-relapsed-refractory-acute-myeloid-leukemia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2017-06-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-06-14",
            "studyFirstSubmitQcDate": "2017-06-15",
            "studyFirstPostDateStruct": {
                "date": "2017-06-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-31",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Cellectis S.A.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)."
        },
        "conditionsModule": {
            "conditions": [
                "Relapsed/Refractory Acute Myeloid Leukemia"
            ],
            "keywords": [
                "Acute Myeloid Leukemia",
                "Relapsed/Refractory Acute Myeloid Leukemia",
                "Chimeric Antigen Receptor T-Cell (CAR-T) therapy",
                "Allogeneic",
                "Transcription Activator-Like Effector Nuclease (TALEN)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 65,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "UCART123v1.2 tested at several dose levels with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)\n\nDose Expansion: UCART123v1.2 administered at the RP2D determined from the dose escalation phase",
                    "interventionNames": [
                        "Biological: UCART123v1.2"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "UCART123v1.2",
                    "description": "Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab",
                    "armGroupLabels": [
                        "Dose Escalation"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]",
                    "description": "Safety of UCART123v1.2 - Incidence, nature, and severity of AE and SAEs throughout the study",
                    "timeFrame": "24 Months"
                },
                {
                    "measure": "Dose escalation and expansion part: Occurrence of DLTs",
                    "timeFrame": "Up to Day 28 post last UCART123v1.2 infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Investigators assessed overall response rate according to the European Leukemia Net (ELN) Response Criteria",
                    "timeFrame": "At Day 28, Day 56, Day 84, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and Month 24"
                },
                {
                    "measure": "Duration of Response",
                    "timeFrame": "From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24"
                },
                {
                    "measure": "Progression Free Survival",
                    "timeFrame": "From the first day of study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24"
                },
                {
                    "measure": "Overall Survival",
                    "timeFrame": "From the first day of study treatment to the date of death from any cause, assessed up to Month 24"
                },
                {
                    "measure": "Pharmacokinetic (PK) Analysis: Standard PK Analysis will be completed to obtain Maximum plasma concentration (Cmax)",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain time to reach Cmax (Tmax)",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain total area under curve from zero to infinity (AUC-infinity)",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Terminal Rate",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Terminal Half-life",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Clearance",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacokinetic Analysis: Standard PK Analysis will be completed to obtain Volume of Distribution",
                    "timeFrame": "alemtuzumab levels will be determined pre- and post-dose alemtuzumab and up to 48 hours after the last dose"
                },
                {
                    "measure": "Pharmacodynamic Analysis: Pharmacodynamics Monitoring of the incidence of anti-cluster of differentiation 52 (anti-CD52; alemtuzumab) antibodies (ADA) in serum Pre-alemtuzumab administration and through Day 84",
                    "timeFrame": "From screening through Day 84"
                },
                {
                    "measure": "Pharmacodynamic Analysis: Pharmacodynamics Quantitation of T cells in peripheral blood",
                    "timeFrame": "From screening through Day 84"
                },
                {
                    "measure": "Pharmacodynamic Analysis: Pharmacodynamics Quantitation of B cells in peripheral blood",
                    "timeFrame": "From screening through Day 84"
                },
                {
                    "measure": "Pharmacodynamic Analysis: Pharmacodynamics Quantitation of natural killer (NK) cells in peripheral blood",
                    "timeFrame": "From screening through Day 84"
                },
                {
                    "measure": "Pharmacodynamic Analysis: Pharmacodynamics Quantitation of total lymphocytes in peripheral blood",
                    "timeFrame": "From screening through Day 84"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Main Inclusion Criteria:\n\n* Patients with relapsed or primary refractory AML (as defined in World Health Organization \\[WHO\\] criteria) with \u22655% bone marrow blasts\n* Patients with CD123+ blast cells (verified by flow cytometry)\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of \u22641\n* Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period\n* (Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)\n* Other criteria may apply\n\nMain Exclusion Criteria:\n\n* Patients with acute promyelocytic leukemia (APL) or central nervous system (CNS) Leukemia\n* Previous investigation gene or cell therapy (including CAR)\n* \\> 1 prior allogeneic stem cell transplantations (SCTs)\n* Prior treatment with rituximab or other anti-cluster of differentiation 20 (anti-CD20) therapy within 3 months\n* Any known active or uncontrolled infection\n* Other criteria may apply",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cellectis Central Contact",
                    "role": "CONTACT",
                    "phone": "1-347-752-4044",
                    "email": "clinicaltrials@cellectis.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gail Roboz, Dr",
                    "affiliation": "Weill Medical College of Cornell University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                },
                {
                    "facility": "Sylvester Comprehensive Cancer Center",
                    "status": "WITHDRAWN",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                },
                {
                    "facility": "H. Lee Moffitt Cancer Center & Research Institute",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Northwestern University",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60201",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Roswell Park Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Buffalo",
                    "state": "New York",
                    "zip": "14263",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.88645,
                        "lon": -78.87837
                    }
                },
                {
                    "facility": "Weill Medical College of Cornell University",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10021",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "University of Pennsylvania - Abramson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007951",
                    "term": "Leukemia, Myeloid"
                },
                {
                    "id": "D000015470",
                    "term": "Leukemia, Myeloid, Acute"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10955",
                    "name": "Leukemia, Myeloid",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18127",
                    "name": "Leukemia, Myeloid, Acute",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3995",
                    "name": "Myeloid Leukemia",
                    "asFound": "Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T182",
                    "name": "Acute Myeloid Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T188",
                    "name": "Acute Non Lymphoblastic Leukemia",
                    "asFound": "Acute Myeloid Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M1347",
                    "name": "Alemtuzumab",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}